Successful management of a sporadic pancreatic insulinoma by endoscopic ultrasound-guided radiofrequency ablation

A 70-year-old woman presented with an 18-month history of recurrent episodes of dizziness that were alleviated by sugary drinks. During one of these episodes, a low blood glucose of 1.6 mmol/L was noted. Her past medical history included atrial fibrillation and severe chronic obstructive pulmonary disease (COPD), necessitating long-term oxygen therapy. Given the high index of suspicion of spontaneous hypoglycemia, further investigations commenced with a supervised 72-hour fast. This confirmed symptomatic hyperinsulinemic hypoglycemia: serum glucose of 1.8 mmol/L (normal range 3–7.8), insulin 17.3 milliunits/L, and C-peptide 2418 pmol/L at 34 hours. The serum sulphonylurea screen was negative. A computed tomography (CT) scan revealed an 18-mm enhancing lesion in the uncinate consistent with a neuroendocrine tumor and this was confirmed by an endoscopic ultrasound with fine needle aspiration (EUS-FNA) (Fig. 1).

The patient was prescribed diazoxide 50mg, but this had to be discontinued because of acute fluid retention. She remained symptomatic but was a poor surgical candidate so was commenced on a low glycemic-index diet and octreotide. This was unsuccessful, so she remained on a continuous infusion of 10% dextrose. The patient was therefore referred for EUS-guided radiofrequency ablation (RFA).

RFA causes thermal coagulative necrosis through the administration of a high frequency current. The technique is now

Table 1 Summary of the three endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) procedures performed in a patient with a pancreatic neuroendocrine tumor.

<table>
<thead>
<tr>
<th>Procedure number</th>
<th>Number of ablations</th>
<th>Individual ablation time, seconds</th>
<th>Procedure time – first ablation to last, minutes</th>
<th>10% dextrose requirements, mL/hour</th>
<th>Tumor volume, cm³</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>120</td>
<td>6</td>
<td>100 (pretreatment)</td>
<td>2.14</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>90</td>
<td>33</td>
<td>15 (post-treatment)</td>
<td>0.52</td>
</tr>
<tr>
<td>3</td>
<td>14</td>
<td>90</td>
<td>55</td>
<td>0 (post-treatment)</td>
<td>0</td>
</tr>
</tbody>
</table>

Fig. 1 Pretreatment imaging showing: a on a computed tomography (CT) scan, an 18-mm round lesion with arterial enhancement, characteristic of a pancreatic neuroendocrine tumor; b the lesion on magnetic resonance imaging (MRI); c a hypoechoic circular lesion on endoscopic ultrasound (EUS).

Fig. 2 a The Habib endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) probe positioned within the insulinoma on: a EUS imaging (note also the 19G fine needle aspiration [FNA] needle at the edge of the insulinoma); b fluoroscopic imaging.
During the second treatment the probe was placed within the tumor in two different planes and eight sequential treatments were administered at 10W. The patient’s glucose requirements immediately halved and repeat imaging showed a larger area of central necrosis, but the edge of the tumor was unchanged. On the third occasion, 14 sequential treatments were administered. After 10 treatments in three planes, a contrast-harmonic EUS with SonoVue (sulfur hexafluoride microbubbles; Bracco UL Ltd., High Wycombe, UK) was performed and revealed tumor remaining within the distal wall, so four further RFA treatments were directed at this area (Fig. 3c). After the final EUS-RFA treatment, the patient’s glucose requirements ceased and octreotide therapy was withdrawn (Table 1).

Before the patient was discharged, a 72-hour supervised fast was completed without hypoglycemia, consistent with biochemical remission. A post-procedural CT scan showed that the lesion had been almost completely replaced by necrotic tissue and a 18F-gallium dotatate positron emission tomography (PET)-CT scan showed that the abnormal uptake within the unincincte process had resolved. The patient was discharged home and remained well and asymptomatic after 10 months. This case supports the use of EUS-RFA in the management of patients with functional pancreatic neuroendocrine tumors who have failed multiple medical therapies and cannot undergo surgery because of comorbidities. Long-term outcomes and further experience is required but this novel approach should be considered for selected patients.

Endoscopy_UCTN_Code_TTT_1AS_2AD

Competing interests: None

Julian A. Waung1, Jeannie F. Todd1, Margaret G. Keane2, Stephen P. Pereira2

1 Imperial Centre for Endocrinology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
2 UCL Institute for Liver and Digestive Health, University College London, London, UK

Acknowledgments

This work was supported by the National Institute for Health Research UCL Hospitals Biomedical Research Centre.

References


Bibliography

DOI http://dx.doi.org/10.1055/s-0042-104650
ISSN 0013-726X

Corresponding author
Stephen Pereira, MD, PhD
UCL Institute for Liver and Digestive Health
Royal Free Campus
Pond Street
London NW3 2QG
UK
stephen.pereira@ucl.ac.uk

Waung Julian A et al. EUS-RFA for pancreatic insulinoma... Endoscopy 2016; 48: E144–E145